Last update 17 Jun 2025

Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms
NEPHSTROM ORBCELM, REDDSTAR ORBCELM
Target-
Action-
Mechanism
Cell replacements
Therapeutic Areas
Endocrinology and Metabolic DiseaseUrogenital DiseasesNervous System Diseases+ [2]
Active Indication-
Inactive Indication
Diabetic FootDiabetic Nephropathies
Originator Organization
Orbsen Therapeutics Ltd.Orbsen Therapeutics Ltd.
Active Organization-
Inactive Organization
Istituto di Ricerche Farmacologiche Mario NegriIstituto di Ricerche Farmacologiche Mario NegriOrbsen Therapeutics Ltd.Orbsen Therapeutics Ltd.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
NCT02585622
/ TerminatedPhase 1/2IIT
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)
100 Clinical Results associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
Login to view more data
100 Translational Medicine associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
Login to view more data
100 Patents (Medical) associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
Login to view more data
100 Deals associated with Allogeneic bone marrow-derived mesenchymal stromal cell therapy (Orbsen Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic NephropathiesPhase 2
Ireland
Istituto di Ricerche Farmacologiche Mario NegriIstituto di Ricerche Farmacologiche Mario Negri
11 Dec 2017
Diabetic NephropathiesPhase 2
Italy
Istituto di Ricerche Farmacologiche Mario NegriIstituto di Ricerche Farmacologiche Mario Negri
11 Dec 2017
Diabetic NephropathiesPhase 2
United Kingdom
Istituto di Ricerche Farmacologiche Mario NegriIstituto di Ricerche Farmacologiche Mario Negri
11 Dec 2017
Diabetic FootPhase 1
Denmark
Orbsen Therapeutics Ltd.Orbsen Therapeutics Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free